NCT03611816

Biological Bank for Atrial Fibrillation and Stroke

Biological Bank for Studies Related to Atrial Fibrillation and Stroke

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 1,000 (estimated)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years. According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted. The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.

Conditions

• Stroke
• Atrial Fibrillation

Interventions

Type	Name	Description
BIOLOGICAL	Blood taken	Collection of clinical data
GENETIC	Blood taken	Collection of DNA
GENETIC	Blood taken	Collection of plasma

Timeline

• Start date: 2018-04-23
• Primary completion: 2033-04-23
• Completion: 2033-04-23
• First posted: 2018-08-02
• Last updated: 2026-04-17

Locations

5 sites across 1 country: France